Longevity Research Edges Toward the Clinic and Toward Measuring Biological Age Cheaply
By Integrated Practitioner Staff
November 19, 2026 | Research out of Harvard’s Wyss Institute for Biologically Inspired Engineering is pushing the science of biological aging in two directions that should interest clinicians who already counsel patients on healthspan: therapies that make old cells behave young, and inexpensive ways to measure how old a patient’s cells actually are.
As reported this month by Bio-IT World, a team including Wyss founding faculty member George Church, PhD, and Alex Plesa, PhD, has flagged an RNA-processing factor SRSF1 as a potent single-gene rejuvenation target. In aged mice, turning the gene on extended median lifespan by roughly 14%, a span the researchers liken to about a decade of human life, and the treated animals reportedly became frail more slowly than untreated controls. Notably, the effect came from a liver-targeted delivery system, suggesting that rejuvenating one organ may ripple outward systemically, a framing that will sound familiar to practitioners who think in terms of organ systems rather than isolated endpoints.
Why The “Clock” Story Matters More For Day-To-Day Practice
Biological age testing has become a fixture of the wellness marketplace, and this is where the Harvard work has the most immediate relevance. Most commercially available clocks rely on DNA methylation. Plesa’s group instead built a transcriptomic clock, reading gene expression rather than methylation marks, and he puts the cost difference starkly: roughly $10 per test versus about $350 for epigenetic testing at scale.
The functional difference may matter even more than the price. Rather than returning a single number, an RNA-based clock can break the score down across cellular processes—stress response, protein translation, maintenance of the epigenome—closer to a panel than a verdict. Plesa compares it to a dashboard of gauges rather than one reading, which is arguably a better fit for the systems-oriented assessment many integrative practitioners already favor.
Church, for his part, is openly skeptical of how aging clocks are currently used. He notes that much of their popularity stems from people’s appetite for measurement, and questions how many are actually improving outcomes, a caution worth passing along to patients arriving with direct-to-consumer biological age results in hand.
Timeline and Caveats
None of this is clinic-ready. Next steps include additional mouse studies to identify age-related diseases SRSF1 might treat, plus safety and toxicology work; first-in-human testing is described as at least several years out. A spinout company, RegulaBio, will pursue fibrosis and liver indications, following a path similar to Rejuvenate Bio, an earlier Church-cofounded venture now approaching its first human trial in cardiomyopathy.
Church’s blunt framing of the stakes — “Aging is going to kill 90% of us” — captures why the field is drawing investment. For now, the practical takeaway for practitioners is less about gene therapy than about what gets measured, how much it costs, and how cautiously the results should be interpreted.
Read Deborah Borfitz’s full story which includes additional detail on the Yamanaka factor work, combination gene approaches, and the underlying Nature Aging study on Bio-IT World.




